知镜 Cognispect · 医学文献与研究工作台

Clinical Validity of Imatinib Therapeutic Drug Monitoring in a Real-World Italian Cohort of Gastrointestinal Stromal Tumors and the Role of Patients' Sex.

Gagno S, Buonadonna A, Cecchin E, Fumagalli A, Posocco B, Canil G, Cecchin R, Guardascione M, Montico M, Puglisi F, Cecchin E.
Pharmaceutics · 2026-08-07 · PMID 42654086

文献摘要

Background : Substantial inter-individual variability in imatinib systemic exposure may influence both efficacy and toxicity. Based on recommendations of the International Association for Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), the IRCCS-CRO of Aviano started in 2018 offering physicians the opportunity to monitor plasma concentrations of imatinib and its active metabolite, norimatinib, as part of a diagnostic service for patients with Gastrointestinal Stromal Tumor (GIST). This study aims to evaluate the potential clinical utility of imatinib Therapeutic Drug Monitoring (TDM) in predicting response and toxicity in a real-world cohort of 63 patients with GIST. Methods : Imatinib and its active metabolite norimatinib trough concentrations (C min ) were quantified using a validated LC-MS/MS method. Associations between drug exposure and clinical-demographic characteristics, treatment-related toxicity, and progression-free survival (PFS) were evaluated. Results : A total of 437 plasma samples from 63 patients were collected. Marked inter- and intra-patient variability in imatinib exposure was observed (43% and 31% respectively); 67% of patients receiving 400 mg/day had a C min below the recommended target concentration (1100 ng/mL). Female sex was significantly associated with higher imatinib exposure (median C min 1114 vs. 786 ng/mL in males; p = 0.0018). Combined age-sex analysis showed a significant difference between women and men p = 0.0068, Bonferroni-adjusted). A strong exposure-toxicity relationship emerged, with higher imatinib levels in samples collected at toxicity occurrence vs. the others (1728 vs. 927 ng/mL; p min and PFS was observed; however, disease progression was more frequent in patients with C min min >1500 ng/mL (60% vs. 0%, respectively). Conclusions : TDM was found to be a potentially useful tool for predicting clinically relevant toxicity and outcome. Sex and age significantly influence exposure, supporting tailored dosing strategies.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。